Onfekafusp alfa
- Generic Name
- Onfekafusp alfa
- Drug Type
- Biotech
- CAS Number
- 1957239-88-1
- Unique Ingredient Identifier
- 6HXC0O6JMV
- Background
Onfekafusp alfa is under investigation in clinical trial NCT02938299 (Neoadjuvant L19IL2/L19TNF- Pivotal Study).
Sun Pharma to Acquire Checkpoint Therapeutics in $355 Million Deal for Novel Skin Cancer Treatment
• Sun Pharmaceutical Industries will acquire Checkpoint Therapeutics for $355 million upfront, with stockholders receiving $4.10 per share plus a contingent value right worth up to $0.70 per share based on European approval milestones.
• The acquisition adds UNLOXCYT (cosibelimab-ipdl), the first and only FDA-approved anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma (cSCC), to Sun Pharma's global onco-dermatology portfolio.
• Sun Pharma plans to leverage its global presence to accelerate patient access to UNLOXCYT in the United States, Europe, and other markets worldwide, addressing a significant unmet need in the second most common skin cancer.
Sun Pharma and Philogen Complete Enrollment for Pivotal Phase III FIBROSARC Trial in Soft Tissue Sarcoma
• Sun Pharmaceutical Industries and Philogen have successfully completed patient enrollment in the Phase III FIBROSARC trial for Soft Tissue Sarcoma, with key readouts expected between March and June 2025.
• The FIBROSARC study, conducted across five European countries, has enrolled 129 patients to evaluate Fibromun in combination with Doxorubicin for first-line treatment of locally advanced or metastatic STS.
• Multiple parallel trials of Fibromun are progressing ahead of schedule, including studies in glioblastoma, with the Phase II GLIOSTAR trial now expected to complete enrollment by Q2 2025.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath